HOME >> BIOLOGY >> NEWS
Experimental drug shown to block mutant protein causing blood disease

BOSTON--Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

The researchers also tested the drug, PKC412, in a patient with the hard-to-treat disease, called Myeloproliferative Disease (MPD), and saw her symptoms improve.

PKC412, like the spotlight drug Gleevec, is a highly specific "targeted" drug that disables a switch in cancer cells that has become jammed in the "on" position because of a genetic mutation. The glitch allows a continuous stream of signals to prod blood cells into an uncontrolled frenzy of division and growth. The overproduction of white blood cells in MPD damages organs and generally turns into an acute leukemia that can be fatal.

The report appears in this week's Online Early Edition of the Proceedings of the National Academy of Sciences. Jing Chen, PhD, of Brigham and Women's, and Daniel J. DeAngelo, MD, PhD, of Dana-Farber, are the paper's co-first authors. D. Gary Gilliland, MD, PhD, a Howard Hughes Medical Institute investigator at Brigham and Women's Hospital, and Richard M. Stone, MD, of Dana-Farber are the senior authors. Other authors are from Dana-Farber, Brigham and Women's, Harvard Medical School, Emory University, and Novartis Pharma AG.

"The study shows the potential utility of drugs that block mutant tyrosine kinases, and that these drugs are opening more doors to treating cancers," explains Stone.

Tyrosine kinases are molecules that act as biological switches inside cells, regulating processes including cell division and growth. Abnormal kinases have been discovered to be major culprits in many forms of cancer. Because inhibitor drugs strike the abnormal kinases in cancer cells without harming normal tissue, they are associated with fewer side effects than standard cancer drugs.

In the study, mice with MP
'"/>

Contact: Bill Schaller or Richard Saltus
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
21-Sep-2004


Page: 1 2

Related biology news :

1. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
2. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
3. Experimental Biology 2004 - Translating the Genome
4. Experimental Biology 2004 meets in Washington, D.C. April 17-21
5. Experimental hantavirus vaccine elicits strong antibody response in primates
6. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/9/2019)... ... July 09, 2019 , ... Murrieta Genomics, a ... incubator program. The founder and CEO of Tx Genetic, Helen Harrison, has spent ... suffering from epithelial connective tissue disorders. , “We are pleased and excited to ...
(Date:6/25/2019)... ... June 25, 2019 , ... ActX ... raw data, easily available from 23andMe, customers can get access to professionally reviewed ... available for both 23andMe Ancestry and Health + Ancestry customers., With the ActX ...
(Date:6/16/2019)... ... June 14, 2019 , ... Respected periodontist, Dr. ... fifth annual Neodent World Congress. Attended by thousands of dental clinicians from all ... in the world of dentistry. The three-day event featured a team of expert ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... City, California (PRWEB) , ... ... ... allowance of our patent applications from the USPTO providing proprietary interest to ... AND METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights ...
(Date:5/22/2019)... ... May 22, 2019 , ... Artemis (formerly Agrilyst), the leading ... A funding round co-led by Astanor Ventures and Talis Capital ... and iSelect Fund . The company has raised $11.75m to date and will ...
(Date:5/14/2019)... TOWNSHIP, N.J. (PRWEB) , ... May 13, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... new Heliumleak.com company website. The redesigned website aims to improve LDA’s ability to ...
(Date:5/4/2019)... SÃO PAULO, Brazil (PRWEB) , ... May 03, ... ... the lecture given by the President of the Dakila Pesquisas Association, the scientist ... of the Councilmen 2019, in Brasília (DF). Urandir detailed the results of some ...
Breaking Biology Technology:
Cached News: